广东君信经纶君厚律师事务所 关于广东永顺生物制药股份有限公司 2024 年年度股东会的 法律意见书 二〇二五年五月 广东君信经纶君厚律师事务所 关于广东永顺生物制药股份有限公司 2024 年年度股东会的法律意见书 致：广东永顺生物制药股份有限公司 广东君信经纶君厚律师事务所（以下简称"本所"）接受广东永顺生物制药 股份有限公司（以下简称"公司"）的委托，指派戴毅、姚亮律师（以下简称"本 所律师"）作为经办律师，出席公司于 2025 年 5 月 23 日召开的 2024 年年度股东 会（以下简称"本次股东会"），并根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会 规则》等法律、法规和规范性文件及公司现行有效的《章程》、《股东会议事规则》 的规定，就本次股东会的召集和召开程序、出席会议人员资格、召集人资格、表 决程序、表决结果等事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的相关文件资料，听取了 公司就有关事实的陈述和说明，并进行了必要的验证。本法律意见书仅供本次股 东会之目的使用，非经本所书面同意，不得用于其他任何 ...

Group 1: Investor Relations Activity - The company held an earnings briefing on May 21, 2025, via the "Investor Relations Interactive Platform" [3] - Key personnel included General Manager Wu Feng, Deputy General Manager and CFO Li Qiuhong, and Secretary of the Board Lin Jianxin [3] Group 2: Market Expansion and Competition - The company aims to enhance market presence through strategic partnerships and optimizing sales networks, targeting both domestic and international markets [4] - Plans include leveraging policy opportunities related to mandatory immunization vaccines and enhancing the marketing system for poultry vaccines to increase market share [4] Group 3: Cost Reduction and Efficiency Improvement - The company has established a closed-loop management system for cost reduction and efficiency improvement across key business areas [5] - Measures include skill training, supplier competition, production process optimization, and energy monitoring to enhance operational efficiency [5] Group 4: Value Management and Governance - The company views value management as a strategic priority, focusing on core business and enhancing technological innovation to support market value growth [6] - A stock incentive plan for 2024 aims to attract and retain talent, enhancing operational efficiency and driving value [7] Group 5: Product Development and R&D - The company is in the early stages of developing pet vaccines and has new products like the H5 subtype avian influenza vaccine and the Bartha-K61 strain vaccine for pigs in preparation for market launch [8][9] - The 2025 product launch plan includes the P-V1 strain inactivated vaccine for pigeons [9] Group 6: Financial Performance and Strategy - The company reported a decline in revenue and net profit due to factors like low pig prices and market demand shrinkage [10] - Future strategies include increasing R&D investment, optimizing production processes, and enhancing service levels to improve profitability [11] Group 7: Market Demand and Regulatory Environment - Rising pig prices may improve vaccine demand, but the response will depend on various factors including government policies and disease trends [12] - The tightening of regulatory standards in the veterinary drug industry may increase short-term costs but could lead to a healthier market structure in the long run [15]

证券代码：839729 证券简称：永顺生物 公告编号：2025-035 广东永顺生物制药股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 广东永顺生物制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 在北京证券交易所指定信息披露平台（www.bse.cn）披露了《广东永顺生物制药 股份有限公司 2024 年年度报告》（公告编号：2025-011）。为方便广大投资者更 深入了解公司 2024 年年度经营业绩的具体情况，加强与投资者的互动交流，公 司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 21 日（星期三）15:00-17:00。 公司总经理：吴锋先生 公司副总经理、财务负责人：李秋红女士 公司副总经理、董事会秘书：林建新先生 四、 投资者参加方式 本次说明会采用网络方式召开。 投资者可登录全景网"投资者关系互动平台"（https://ir.p ...

Core Insights - Yongshun Bio achieved operating revenue of 269 million yuan and net profit of 40 million yuan in 2024, maintaining a steady operational trend [1] - The company has successfully expanded its overseas revenue, surpassing 20 million yuan for the first time [1] - In Q1 2025, Yongshun Bio reported operating revenue of 65.46 million yuan and net profit attributable to shareholders of 7.92 million yuan, continuing its stable performance [1] Product and Market Position - Yongshun Bio is a leading domestic veterinary biological product company, focusing on swine and poultry vaccines with over 30 product varieties [2] - The company holds a strong market position in core products, with significant market shares in swine vaccines, particularly the classical swine fever live vaccine and the three-in-one vaccine for swine [2] - Key products such as the pseudorabies live vaccine and the porcine circovirus type 2 inactivated vaccine saw substantial sales growth, with revenues of 14.91 million yuan (up 35.47%) and 8.12 million yuan (up 71.71%) respectively in 2024 [2] Financial and Operational Efficiency - Yongshun Bio has optimized its financial structure, reducing total liabilities by 16.35% compared to the beginning of the year, enhancing its balance sheet [2] - The company invested 23 million yuan in R&D in 2024, accounting for 8.54% of its operating revenue, and obtained new drug registration certificates and patents, enriching its product line [3] - The production system has undergone technological innovation and management upgrades, with successful GMP dynamic acceptance of its bacterial inactivated vaccine production line [3] International Expansion - Yongshun Bio has successfully registered new products in Egypt, adding to its international presence alongside Vietnam, with a total of 7 and 2 products registered in these countries respectively [4] - The company’s overseas revenue reached over 20 million yuan in 2024, marking a year-on-year growth of 34.31%, indicating an increasing contribution from international markets [4]

Financial Performance - The company's basic earnings per share decreased to 0.1500 yuan in 2024 from 0.2100 yuan in 2023, representing a decline of 28.57% [1] - The net profit for 2024 was 0.4 billion yuan, down 31.03% from 0.58 billion yuan in 2023 [1] - Operating revenue fell to 2.69 billion yuan in 2024, a decrease of 14.33% compared to 3.14 billion yuan in 2023 [1] - The return on equity (ROE) dropped to 6.08% in 2024 from 8.61% in 2023, marking a decline of 29.38% [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 14.1447 million shares, accounting for 17.6% of the circulating shares, which is a decrease of 1.1042 million shares from the previous period [1] - Guangdong Yongshun Biopharmaceutical Co., Ltd. remains unchanged with 360.00 million shares, representing 4.48% of total share capital [2] - Cai Jianping's holdings decreased by 22.00 million shares, now totaling 319.97 million shares, or 3.98% of total share capital [2] Dividend Distribution - The company announced a dividend distribution plan of 1.3 yuan per share (including tax) [2]

（二）召集人 证券代码：839729 证券简称：永顺生物 公告编号：2025-028 广东永顺生物制药股份有限公司 关于召开 2024 年年度股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2024 年年度股东会。 本次股东会的召集人为董事会。 （三）会议召开的合法性、合规性 本次会议的议案已于 2025 年 4 月 25 日经公司第五届董事会第九次会议审议 通过。公司本次股东会的召集人资格及召集程序符合《公司法》及有关法律法规 和《公司章程》等有关规定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 同一表决权只能选择现场投票和网络投票方式中的一种。同一表决权出现 重复表决的以第一次投票结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 5 月 23 日 14：30。 2、网络投票起止时间：2025 年 5 月 22 日 15:00—2025 年 5 月 23 日 15:00 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-029 广东永顺生物制药股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的参与表决监事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 1.议案内容： 根据《公司法》《公司章程》等有关规定，公司监事会对 2024 年度开展的工 作进行了总结回顾，编制了《2024 年度监事会工作报告》。 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出监事会会议通知的时间和方式：2025 年 4 月 15 日以书面方式发出 5.会议主持人：监事会主席梅双 6.召开情况 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-007 广东永顺生物制药股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出董事会会议通知的时间和方式：2025 年 4 月 15 日以书面方式发出 5.会议主持人：董事长谭德明 6.会议列席人员：公司监事、公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的参与表决董事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 6 人，出席和授权出席董事 6 人。 二、议案审议情况 （一）审议通过《关于 2024 年度董事会工作报告的议案》 1.议案内容： 根据《公司章程》以及《董事会议事规则》的相关规定，公司董事会总结 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-013 广东永顺生物制药股份有限公司 公司本次权益分派预案如下：公司目前总股本为 273,350,000 股，以未分配 利润向全体股东每 10 股派发现金红利 1.3 元（含税）。本次权益分派共预计派发 现金红利 35,535,500 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整分派总额。 实际分派结果以中国证券登记结算有限责任公司北京分公司核算的结果为准。 二、最近三年现金分红情况 公司合并资产负债表、母公司资产负债表中本年末未分配利润为正值且报告 期内盈利，最近三年已分配及拟分配的现金红利总额（包括以现金为对价，采用 集中竞价方式、要约方式已实施的股份回购金额 28,801,567.63 元共计 188,473,174.35元，占最近三年年均归属于上市公司股东的净利润比例为306.75%, 超过 30%。 三、审议及表决情况 2024 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并 ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was ¥7,916,030.82, a decrease of 5.47% year-on-year[8]. - Operating revenue for Q1 2025 was ¥65,456,650.96, down 1.56% from ¥66,495,478.87 in Q1 2024[8]. - The net profit for the first quarter of 2025 is 7,916,030.82, a decrease of 5.48% compared to 8,374,511.51 in the same period of 2024[35]. - The total profit for the first quarter of 2025 is 8,711,054.06, down from 9,420,501.30 in the first quarter of 2024, representing a decline of 7.51%[35]. - The operating profit for the first quarter of 2025 is 8,718,430.12, slightly lower than 9,360,944.99 in the same period of 2024[35]. - Basic and diluted earnings per share remain unchanged at 0.03 for both the first quarter of 2025 and 2024[36]. - The total comprehensive income attributable to the parent company for the first quarter of 2025 is 7,916,030.82, compared to 8,374,511.51 in the first quarter of 2024[36]. Assets and Liabilities - Total assets as of March 31, 2025, reached ¥789,010,699.45, an increase of 3.76% compared to the end of the previous year[8]. - Current assets totaled CNY 601,207,705.58 as of March 31, 2025, up from CNY 564,818,676.77 at the end of 2024, reflecting a growth of 6.45%[31]. - Total assets increased to CNY 789,010,699.45 as of March 31, 2025, compared to CNY 760,429,656.42 at the end of 2024, marking a growth of 3.92%[32]. - Total liabilities rose to CNY 118,259,419.58 as of March 31, 2025, compared to CNY 99,800,423.50 at the end of 2024, indicating a significant increase of 18.43%[33]. - The total liabilities to assets ratio remained stable at 14.99% for both the parent and consolidated entities[8]. Cash Flow - The company's cash flow from operating activities increased by 3.35% to ¥17,062,453.70 compared to the same period last year[8]. - The cash flow from operating activities for the first quarter of 2025 is 17,062,453.70, an increase from 16,510,126.57 in the first quarter of 2024[36]. - The total cash outflow from operating activities in the first quarter of 2025 is 46,336,875.46, compared to 51,340,444.49 in the first quarter of 2024[36]. - The cash inflow from investment activities in the first quarter of 2025 is 120,362,370.26, significantly higher than 46,599,181.42 in the same period of 2024[36]. - The net cash flow from investment activities for the first quarter of 2025 is -46,677,987.64, compared to a positive 15,594,454.42 in the first quarter of 2024[37]. - Cash and cash equivalents decreased to CNY 22,468,586.94 from CNY 36,593,830.46, a decline of 38.67%[31]. - The cash and cash equivalents at the end of the first quarter of 2025 amount to 22,318,586.94, down from 205,772,155.39 at the end of the first quarter of 2024[37]. Shareholder Information - The largest shareholder, Guangdong Provincial Agricultural Group, holds 106,780,769 shares, accounting for 39.06% of the total shares[17]. - The second largest shareholder, Guangdong Agricultural Science Assets Management Co., Ltd., holds 53,872,000 shares, representing 19.71% of the total shares[17]. - The third largest shareholder, Guangdong Academy of Agricultural Sciences Animal Health Research Institute, holds 30,799,999 shares, which is 11.27% of the total shares[17]. - There are no pledges or judicial freezes on shares held by shareholders with more than 5% ownership[19]. - The company has no ongoing litigation, arbitration, or external guarantees during the reporting period[21]. - The company has fulfilled all previously disclosed commitments without any overdue situations[28]. Stock Information - The total number of unrestricted shares decreased from 80,425,041 to 76,825,041, representing a change of -3,600,000 shares, which is a reduction of approximately 4.48%[14]. - The total number of restricted shares increased from 192,924,959 to 196,524,959, reflecting an increase of 3,600,000 shares, which is an increase of about 1.87%[14]. - The total share capital remains unchanged at 273,350,000 shares[14]. - The company implemented a stock incentive plan in 2024, granting 3,600,000 restricted shares to 33 individuals, which is approximately 1.32% of the total share capital[24]. Expenses - The company's financial expenses increased by 89.18% to -¥107,316.35, primarily due to adjustments in financial product structures[10]. - Total operating costs for Q1 2025 were CNY 58,827,999.72, an increase of 2.19% from CNY 57,569,882.86 in Q1 2024[34]. - R&D expenses for Q1 2025 were CNY 5,153,474.56, slightly down from CNY 5,350,715.65 in Q1 2024[34]. - The company experienced a 337.53% increase in other payables, reaching ¥18,352,203.48, mainly due to equity incentive contributions[10]. - Non-recurring gains and losses for the period amounted to ¥2,535,421.70 after tax[12].